Evidence map›Paper›PMID 40041678›Full record

ArticleClinical and translational radiation oncology2025

Comparison of

Albert Everard, Daniel Versnel, Veerle Ruijters, Nelleke Tolboom, Marielle Philippens, Tom Snijders, Joost Verhoeff, Szabolcs David, Casper Beijst

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. FET-PETTranslational cancer research · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Albert EverardDepartment of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100 3584 CX Utrecht, The Netherlands.
Daniel VersnelDepartment of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100 3584 CX Utrecht, The Netherlands.
Veerle RuijtersDepartment of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Nelleke TolboomDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht 3584 CX Utrecht, The Netherlands.
Marielle PhilippensDepartment of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100 3584 CX Utrecht, The Netherlands.
Tom SnijdersDepartment of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Joost VerhoeffDepartment of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100 3584 CX Utrecht, The Netherlands.
Szabolcs DavidDepartment of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100 3584 CX Utrecht, The Netherlands.
Casper BeijstDepartment of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100 3584 CX Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: The target area definition for re-irradiation of recurrent glioma typically relies on T1-weighted gadolinium-enhanced MRI (T1Gd), but T1Gd fails to capture glioma infiltration. While T2 FLAIR and CTV margins can address this limitation, their extend in re-irradiation remains debated to minimize toxicity. In contrast, Material and methods: Retrospective data from 36 patients with recurrent glioma were used. These patients underwent Results: BTV Conclusion: Our results suggest that

Indexed as

Biological tumor volumeDiffuse gliomaFET-PETRecurrenceRe-irradiationTissue composition

Identifiers

PMID40041678
PMCPMC11879608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.